Tweets
1st #recommendations for
#Hemochromatosis #arthropathy
#psuedogout
#CPPD
#calcium #pyrophosphate #arthritis
#EULAR2025 #Recommenadations II
@RheumNow @eular_org https://t.co/AnE4T2wYoa
Janet Pope @Janetbirdope ( View Tweet )
7 months 1 week ago
67% of HCPs knew of EULAR’s CVD risk guidelines in RMDs—but few could apply them.
✅ Only 13% linked SLE control to CVD risk
🚫 0% picked correct BP/statin use in RA/AS/PsA
Barriers? Time, knowledge, and local guideline gaps.
POS0410-HPR @RheumNow #EULAR2025
Jiha Lee @JihaRheum ( View Tweet )
7 months 1 week ago
#Relapsing_Polychondritis
Main differential diagnosis is GPA
🔺️No ANCA and no renal involvement in relapsing polychondritis
@Lupusreference
#EULAR2025
@RheumNow https://t.co/QUJZ3EDjj3
Nelly ZIADE 🍀 @Nellziade ( View Tweet )
7 months 1 week ago
“That is why this task force continues to say: nothing is better than methotrexate and glucocorticoids to start”
- Josef Smolen, on RA treatment
#EULAR2025 @RheumNow https://t.co/AbkgWS8tvH
Links:
David Liew @drdavidliew ( View Tweet )
7 months 1 week ago
The key changes for the new 2025 EULAR recommendations on RA treatment
#EULAR2025 @RheumNow https://t.co/dp5LnoFdpW
David Liew @drdavidliew ( View Tweet )
7 months 1 week ago
#EULAR new #RA #recommendations
J Smolen presents justification for
#MTX +#glucocorticoids at onset
do you agree?
Diff from #ACR
#EULAR #Recommendations II
#EULAR2025 @RheumNow https://t.co/wqCX5HA87q
Janet Pope @Janetbirdope ( View Tweet )
7 months 1 week ago
URAT1 inhibitors look like the way to go in Gout!
Presented in multiple abstracts at #EULAR2025
Pozdeutinurad Ph2 long term safety data chronic gouty arthritis + tophi OP0300
Ph3 RCT of Ruzinurad in hyperuricemia/primary gout OP0302
Ph 2b RCT of SAP-001 Refractory Gout +/-
Aurelie Najm @AurelieRheumo ( View Tweet )
7 months 1 week ago
EULAR Points to consider for the definition of #D2M #Psoriatic_Arthritis
1️⃣ Failure >= 2 b/tsDMARDs with >=2 different MOA
2️⃣ Perceived as problematic
3️⃣ Evidence of persistent disease (active disease, EMM, inflammation)
#EULAR2025
@RheumNow https://t.co/69nFEYntF0
Nelly ZIADE 🍀 @Nellziade ( View Tweet )
7 months 1 week ago
EULAR PtC for the definition of #TR (Trt Refractory) #Psoriatic_Arthritis
#D2M
1️⃣ Failure >= 2 b/tsDMARDs
2️⃣ Problematic
3️⃣ Evidence of persistent disease (inflammation is mandatory)
+
4️⃣ Exclude comorbidities, psychosocial factors, failure due to SE/CI
#EULAR2025
@RheumNow https://t.co/8nx26mWX3C
Nelly ZIADE 🍀 @Nellziade ( View Tweet )
7 months 1 week ago
@RheumNow When it comes to ORAL Surveillance and the 2025 EULAR recommendations, the same sensibility remains.
Appropriate caution based on the RCT, despite observational data, but we’ll see what is yet to come. Plenty to watch this space for
#EULAR2025 @RheumNow https://t.co/fIxHRGDFcK
Links:
David Liew @drdavidliew ( View Tweet )
7 months 1 week ago
Deucravacitinib, the first oral TYK2 inhibitor, delivers in PsA:
✅ ACR20: 54% vs 34% (placebo)
✅ Skin, joints, fatigue, QoL
📉 Post hoc: less radiographic progression
No new safety signals at W16.
LB0001 @RheumNow #EULAR2025
Jiha Lee @JihaRheum ( View Tweet )
7 months 1 week ago
📊 In POETYK PsA-1, deucravacitinib (TYK2i) significantly improved ACR20 at W16 (54% vs 34% placebo) in bDMARD-naive PsA.
Also improved QoL, skin, and MSK outcomes.
Post hoc: slowed radiographic progression.
Well tolerated & no new safety signals
@RheumNow #EULAR2025 #LB0001
Mrinalini Dey @DrMiniDey ( View Tweet )
7 months 1 week ago
